Qed Therapeutics
Biotechnology, 421 Kipling St, Palo Alto, California, 94301, United States, 11-50 Employees
Phone Number: 65********
Who is QED THERAPEUTICS
QED Therapeutics, an affiliate company of BridgeBio Pharma, is dedicated to developing meaningful treatment options for those with achondroplasia and pursuing research to address the need...
Read More
-
Headquarters: 421 Kipling St, Palo Alto, California, 94301, United States
-
Date Founded: 2018
-
Employees: 11-50
-
Revenue: $25 Million to $50 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
|
NAICS Code: 813990 |
Show More
Does something look wrong? Fix it. | View contact records from QED THERAPEUTICS
QED Therapeutics Org Chart and Mapping
Email
Phone
Similar Companies to QED Therapeutics
Allogene Therapeutics
-
201-500
-
$ 1 Million to 5 Million
Beam Therapeutics
-
501-1000
-
$ 50 Million to 100 Million
bluebird bio
-
201-500
-
$ 1 Million to 5 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding QED Therapeutics
Answer: QED Therapeutics's headquarters are located at 421 Kipling St, Palo Alto, California, 94301, United States
Answer: QED Therapeutics's phone number is 65********
Answer: QED Therapeutics's official website is https://qedtx.com
Answer: QED Therapeutics's revenue is $25 Million to $50 Million
Answer: QED Therapeutics's SIC: 8731
Answer: QED Therapeutics's NAICS: 813990
Answer: QED Therapeutics has 11-50 employees
Answer: QED Therapeutics is in Biotechnology
Answer: QED Therapeutics top competitors include: Allogene Therapeutics , Beam Therapeutics , bluebird bio
Answer: QED Therapeutics contact info: Phone number: 65******** Website: https://qedtx.com
Answer: QED Therapeutics, an affiliate company of BridgeBio Pharma, is dedicated to developing meaningful treatment options for those with achondroplasia and pursuing research to address the needs of the community. We are studying whether an investigational agent (infigratinib) has the potential to address the root cause of irregular bone growth in achondroplasia, by decreasing the overactivity of the FGFR3 receptor.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month